Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
397
-
Total 13F shares, excl. options
-
47,170,730
-
Shares change
-
-846,421
-
Total reported value, excl. options
-
$7,222,892,447
-
Value change
-
+$35,286,644
-
Put/Call ratio
-
102%
-
Number of buys
-
235
-
Number of sells
-
-120
-
Price
-
$153.11
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2020
464 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2020.
CRISPR Therapeutics AG - Common Stock (CRSP) has 397 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47,170,730 shares
of 90,438,636 outstanding shares and own 52% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (10,412,976 shares), Capital International Investors (7,426,716 shares), Nikko Asset Management Americas, Inc. (3,836,823 shares), Versant Venture Management, LLC (3,040,462 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,774,436 shares), NEA Management Company, LLC (1,590,002 shares), WADDELL & REED FINANCIAL INC (1,214,102 shares), BlackRock Inc. (1,173,259 shares), Bellevue Group AG (909,684 shares), and FMR LLC (907,789 shares).
This table shows the top 397 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.